DiaSorin S p A : launches the LIAISON® B·R·A·H·M·S MR-proADM™ assay in all countries accepting the CE Mark

DIASORIN LAUNCHES THE LIAISON® B·R·A·H·M·S MR-PROADM™ ASSAY IN ALL COUNTRIES ACCEPTING THE CE MARK TO IMPROVE PATIENT MANAGEMENT BY PROVIDING THE ASSESSMENT OF DISEASE SEVERITY

THE LIAISON® B·R·A·H·M·S MR-PROADM™ASSAY:

• IS A HIGHLY AUTOMATED DIAGNOSTIC SOLUTION TO AID IN THE ASSESSMENT OF DISEASE SEVERITY;
• SUPPORTS THE PROCESS OF HOSPITAL ADMISSION AND IMPROVES PATIENT MANAGEMENT IN EMERGENCY DEPARTMENTS (EDS) AND INTENSIVE CARE UNITS (ICUS);
• IS DEVELOPED TO RUN ON THE LIAISON® CLIA ANALYZER FAMILY;
• IS LAUNCHED IN ALL COUNTRIES ACCEPTING THE CE MARK.

Saluggia, June 13, 2023 - DiaSorin (FTSE MIB: DIA) announces the launch of the new LIAISON® B·R·A·H·M·S MR-proADM™ immunodiagnostic assay in all countries accepting the CE Mark. The assay improves patients' management providing a more precise assessment of disease severity and related risk for unfavourable outcomes.

MR-proADM is a biomarker that is released during inflammatory processes and infections. Supported by extensive literature and by a robust evidence base, MR-proADM can improve medical risk stratification leading to better decision making on required level of care.

In conjunction with other clinical evaluation and laboratory diagnostic findings, the LIAISON® B·R·A·H·M·S MR-proADM™ assay is indicated for use as an aid in the diagnosis of a number of severe conditions, such as sepsis, septic shock, kidney diseases, lower respiratory and urinary tract infections.

Delayed triaging of patients suffering a suspected infection upon emergency department presentation can result in prolonged hospitalization, increased morbidity, and higher infection-related mortality especially in the presence of sepsis. Therefore, an accurate and rapid diagnostic assessment of disease severity is critical to both initiate an individualized therapy and improve patient triage.

The test is performed on the LIAISON® CLIA platforms and offers a highly automated solution for both the EDs and ICUs. In EDs, LIAISON® B·R·A·H·M·S MR-proADM™ assay can be used to support hospital admission against outpatient management decisions. In addition, in ICUs, the test can help to de-escalate intensity of care, identify clinically stable patients and, in some cases, to allow earlier ICU discharge, therefore resulting in a more efficient utilization of critical care resources.

"We are proud to announce the launch of the new LIAISON® B·R·A·H·M·S MR-proADM™ assay with Thermo Fisher Scientific, which confirms our ability to expand DiaSorin's offering of innovative specialty tests with a high medical value" commented Chen Even, Chief Commercial Officer of DiaSorin. "We are confident that the new test will support clinical decision making as well as optimize critical care resourcing, the latter being a key objective to improving healthcare systems".

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 39 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info atwww.diasoringroup.com